ARCHIVES

NCI to Press FDA For Quicker Drug Approval, Relaxation Of Survival Impact Requirement

This article is from The Cancer Letter archive.

Vol. 13 No. 26 | June 26, 1987

Download PDF Visit The Full Archive

Related Articles

NIH May Claim BRCA1 Rights, While Myriad Files For Patent

October 7, 1994

Other Contract Concepts Approved By DCE Board

March 10, 1989

In Brief: Glantz, Waxman, Wigand honored For Work Opposing tobacco; CTRC Names Executives

February 16, 1996

NCI Director Defends Goal to Eliminate Suffering, Death From Cancer by 2015

June 13, 2003

Three Cancer Centers Test Targeted Therapy For Resistant Acute Myelogenous Leukemia

July 26, 2002

ODAC Recommends Approval of Evista for Breast Cancer Risk Reduction.

July 27, 2007